Anika Therapeutics, Inc. 

(Public, NASDAQ:ANIK)   Watch this stock   
Find more results for ANIK
Oct 28, 2009
Q3 2009 Conference Call - Webcast
Oct 27, 2009
Q3 2009 Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 14.02% 10.15%
Operating margin 18.69% 11.81%
EBITD margin - 15.82%
Return on average assets 6.31% 4.14%
Return on average equity 9.52% 6.27%
Employees 84 -

Address

160 New Boston Street
Woburn, MA 01801
United States - Map
+1-781-9326616 (Phone)
+1-781-9354120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Anika Therapeutics, Inc. discussions

  View all discussions »

Description

Anika Therapeutics, Inc. (Anika) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Its manufactured and marketed products consist of ORTHOVISC, which is an HA product used in the treatment of some forms of osteoarthritis in humans; AMVISC, AMVISC Plus, STAARVISC-II and ShellGel, each an injectable ophthalmic viscoelastic HA product; HYVISC, which is an HA product used in the treatment of equine osteoarthritis, and INCERT, an HA-based, anti-adhesive for surgical applications. ORTHOVISC mini, a treatment for osteoarthritis targeting small joints is available in Europe. MONOVISC, a single-injection osteoarthritis product based on its cross-linking technology is available in Europe and Turkey.

Officers and directors

Charles H. Sherwood Ph.D.
President, Chief Executive Officer, Director
Age: 62
Bio & Compensation - Reuters
Kevin W. Quinlan
Chief Financial Officer, Treasurer, Secretary
Age: 59
Bio & Compensation - Reuters
Frank J. Luppino
Chief Operating Officer
Age: 38
Bio & Compensation - Reuters
Randall W. Wilhoite
Vice President - Operations
Age: 43
Bio & Compensation - Reuters
William J. Mrachek
Vice President - Human Resources
Age: 65
Bio & Compensation - Reuters
Irina B. Kulinets
Vice President - Regulatory and Clinical Affairs
Age: 54
Bio & Compensation - Reuters
Andrew J. Carter Ph.D.
Chief Technology Officer
Age: 53
Bio & Compensation - Reuters
Joseph L. Bower Ph.D.
Lead Director
Age: 70
Bio & Compensation - Reuters
Eugene A. Davidson Ph.D.
Director
Age: 78
Bio & Compensation - Reuters
Steven E. Wheeler
Director
Age: 62
Bio & Compensation - Reuters